Actively Recruiting
Phase 1 Open-Label Study of Saroglitazar Magnesium in Adults with Hepatic Impairment and Cirrhosis Due to Cholestatic Liver Disease
Led by Zydus Therapeutics Inc. · Updated on 2026-09-14
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate Saroglitazar Magnesium in adults with hepatic impairment and cirrhosis caused by cholestatic liver disease. It is a Phase 1, open-label extension study designed to assess the drugs pharmacokinetics and safety in this specific population, following discussions with the FDA. The study includes participants with varying degrees of liver impairment and healthy controls to better understand the drugs effects in these groups. Participants receive Saroglitazar Magnesium tablets daily for 28 consecutive days, administered once each morning before breakfast without food. There are two dosage groups one receiving 1 mg and another receiving 2 mg of the drug. Subjects are classified into subgroups according to the severity of hepatic impairment or normal liver function. The study follows a parallel design without randomization or masking. During the trial, researchers collect blood samples on the first and twenty-eighth days to analyze the drug and its metabolites plasma levels over 24 hours. Additional blood samples are collected on days 8, 15, 22, and 35 to measure trough plasma concentrations. Safety and tolerability are monitored throughout the approximately nine-week study period. The trial involves clinical assessments and laboratory tests to ensure participant well-being and to evaluate the drugs behavior in the body.
CONDITIONS
Brief Title
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
Research Team
F
Farheen Shaikh
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here